Primary outcome of Paediatric MS is not achieved with TeriflunomideTeriflunomide (Aubagio) holds a license for adult RRMS with an efficacy of roughly 30% relapse rate reduction versus placebo (dummy tablet). The long#Multiple Sclerosis·disorders.solutions·Nov 27, 2021Primary outcome of Paediatric MS is not achieved with Teriflunomide